Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities–the <scp>BEGAMI</scp> study

Hage, Camilla; Brismar, Kerstin; Efendić, Suad; Lundman, Pia; Rydén, Lars; Mellbin, Linda

doi:10.1111/joim.12032

Cited by 22 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Обнадеживает пилотное сообщение об использо-вании с этой целью ситаглиптина у пациентов с впервые выявленными НУО (с помощью ОГТТ на 4-23-й день, медиана -6-й день) у пациентов с ОКС. В плацебо-кон-тролируемом 12-недельном BEGAMI study у пациентов (n = 71) с ОКС и впервые диагностированными НУО, СД2 и НТГ было показано значимое улучшение глюкозного метаболизма на фоне лечения ситаглиптином (р = 0,003) при хорошей его переносимости [54].…”

Section: в Digami-2 доказано что уровень гпн в остром периоде им явлunclassified

Problems of hypoglycemic therapy in diabetic patients with acute coronary syndrome

Руяткина¹,

Руяткин²,

Ovsyannikova³

2016

Med. sov.

View full text Add to dashboard Cite

Section: в Digami-2 доказано что уровень гпн в остром периоде им явлunclassified

Problems of hypoglycemic therapy in diabetic patients with acute coronary syndrome

Руяткина¹,

Руяткин²,

Ovsyannikova³

2016

Med. sov.

View full text Add to dashboard Cite

“…Beta-cell function in Glucose abnormalities and Acute Myocardial Infarction was a 12-wk multicentre, doubleblind, randomized, parallel group study that investigated the effects of sitagliptin 100 mg daily (n = 34) compared to placebo (n = 37) in 71 patients with acute coronary syndrome having IGT or T2D [59] . Investigation of β-cell function was achieved using the insulinogenic index (IGI) derived from an OGTT and acute insulin response to glucose (AIRg) after a frequently sampled IVGTT.…”

Section: Sitagliptinmentioning

confidence: 99%

Incretin-based therapies in prediabetes: Current evidence and future perspectives

Papaetis¹

2014

WJD

View full text Add to dashboard Cite

The prevalence of type 2 diabetes (T2D) is evolving globally at an alarming rate. Prediabetes is an intermediate state of glucose metabolism that exists between normal glucose tolerance (NGT) and the clinical entity of T2D. Relentless β-cell decline and failure is responsible for the progression from NGT to prediabetes and eventually T2D. The huge burden resulting from the complications of T2D created the need of therapeutic strategies in an effort to prevent or delay its development. The beneficial effects of incretin-based therapies, dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, on β-cell function in patients with T2D, together with their strictly glucose-depended mechanism of action, suggested their possible use in individuals with prediabetes when greater β-cell mass and function are preserved and the possibility of β-cell salvage is higher. The present paper summarizes the main molecular intracellular mechanisms through which GLP-1 exerts its activity on β-cells. It also explores the current evidence of incretin based therapies when administered in a prediabetic state, both in animal models and in humans. Finally it discusses the safety of incretin-based therapies as well as their possible role in order to delay or prevent T2D.© 2014 Baishideng Publishing Group Inc. All rights reserved. Key words:Type 2 diabetes; Prediabetes; Impaired fasting glucose; Impaired glucose tolerance; Glucagonlike peptide-1; Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 receptor agonists Core tip: The beneficial effects of incretin-based therapies on β-cell function in patients with type 2 diabetes (T2D) suggested their possible use in individuals with prediabetes, when greater β-cell mass and function are preserved. Both dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists have demonstrated improvements on β-cell function both in preclinical studies and short-term clinical studies. Until future date for their safety are available, large, long term, prevention trials will be required in order to determine whether they can stabilize or reverse β-cell loss and promote a sustained reduction in the development of T2D in this population.Papaetis GS. Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes 2014; 5(6): 817-834 Available from:

show abstract

“…In a study by Abualsuod et al, the use of metformin in patients with diabetes was associated with a lower 30-day all-cause mortality and tendency for a lower 12-month all-cause mortality following AMI [38]. Hage et al showed that sitagliptin improved beta-cell function and glucose perturbations in patients with acute coronary syndromes and newly diagnosed abnormal glucose tolerance [39]. Acarbose reduced the risk of MACE in patients with acute coronary syndromes and newly detected impaired glucose tolerance [40].…”

Section: Hypoglycemic Treatment In Patients With Ami and Newly Detectmentioning

confidence: 99%

Glucose abnormalities detected by oral glucose tolerance test in patients with acute myocardial infarction: clinical significance, epidemiology, natural course and therapeutic concerns

Francuz

Podolecki

Szymała

et al. 2017

Ann. Acad. Med. Siles.

View full text Add to dashboard Cite

AB ST R ACTTwo-hour post load glycemia (2h-PG) obtained during the oral glucose tolerance test (OGTT) is related to adverse cardiovascular outcomes more significantly than fasting glycemia, and the association of 2h-PG with cardiovascular morbidity is graded and independent. An abnormal value of 2h-PG is defined as glycemia ≥ 7.8 mmol/l (140 mg/dl) in most studies. Patients with acute myocardial infarction with abnormal 2h-PG compared to patients with normal 2h-PG have a significantly higher long-term mortality and more concomitant diseases, however, it has not been shown that those subjects have a higher risk of myocardial infarction, coronary revascularization or stroke. Studies have shown that in some patients the glucometabolic status changes after the acute phase of the disease, and that those changes have a prognostic importance. In this review article the authors presented the significance, epidemiology, natural course of glucometabolic disturbances and the therapeutic concerns of hypoglycemic treatment. K E Y W O R D Sacute myocardial infarction, oral glucose tolerance test, glucometabolic disturbances

show abstract

Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities–the BEGAMI study

Abstract: Abstract. Hage C, Brismar K, Efendic S, Lundman P, Ryd en L,

Cited by 22 publications

References 36 publications

Problems of hypoglycemic therapy in diabetic patients with acute coronary syndrome

Problems of hypoglycemic therapy in diabetic patients with acute coronary syndrome

Incretin-based therapies in prediabetes: Current evidence and future perspectives

Glucose abnormalities detected by oral glucose tolerance test in patients with acute myocardial infarction: clinical significance, epidemiology, natural course and therapeutic concerns

Contact Info

Product

Resources

About